St Vincent's Health Network

Finalist: Health Research Award

The ENZA-p trial tests if combining enzalutamide with Lu PSMA 617 is effective for treating metastatic castrate-resistant prostate cancer (mCRPC).

The goal is to improve treatment responses, reduce adverse effects, and improve pain management and quality of life for patients. This trial also aims to use advanced research methods to create personalised treatment plans.

Led by Professor Louise Emmett from St Vincent’s Health Network, the trial involves 15 centres across Australia. It is conducted in collaboration with Australian and New Zealand Urogenital and Prostate cancer trials and funded by Movember, the federal government, and Novartis.

Patients are randomly assigned to receive either enzalutamide alone or enzalutamide combined with 2 or 4 doses of Lu PSMA 617. The trial uses advanced techniques like molecular imaging and analysis of circulating tumor cells and DNA to personalize treatments and create predictive models.

Interim results published in Lancet Oncology show that when compared to enzalutamide alone, the combination:

• improved treatment response duration and depth
• reduced grade 3 or higher adverse events, and
• enhanced pain control.

These findings suggest that personalised combination therapies could improve mCRPC treatment and patient outcomes. Further analyses on overall survival and quality of life are underway and will be presented at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025.​​